119 related articles for article (PubMed ID: 24231127)
21. Generation and validation of murine monoclonal and camelid recombinant single domain antibodies specific for human pancreatic glycoprotein 2.
Schlör A; Holzlöhner P; Listek M; Grieß C; Butze M; Micheel B; Hentschel C; Sowa M; Roggenbuck D; Schierack P; Füner J; Schliebs E; Goihl A; Reinhold D; Hanack K
N Biotechnol; 2018 Oct; 45():60-68. PubMed ID: 29635104
[TBL] [Abstract][Full Text] [Related]
22. Identification of pancreatic glycoprotein 2 as an endogenous immunomodulator of innate and adaptive immune responses.
Werner L; Paclik D; Fritz C; Reinhold D; Roggenbuck D; Sturm A
J Immunol; 2012 Sep; 189(6):2774-83. PubMed ID: 22891285
[TBL] [Abstract][Full Text] [Related]
23. PR3-ANCA: a promising biomarker for ulcerative colitis with extensive disease.
Mahler M; Bogdanos DP; Pavlidis P; Fritzler MJ; Csernok E; Damoiseaux J; Bentow C; Shums Z; Forbes A; Norman GL
Clin Chim Acta; 2013 Sep; 424():267-73. PubMed ID: 23806819
[TBL] [Abstract][Full Text] [Related]
24. [Organ-specific antibodies in children with idiopathic inflammatory bowel disease and their use in clinical practice].
Sýkora J; Varvarovská J; Stozický F; Haschová M; Hanzlíková J
Cas Lek Cesk; 2000 Nov; 139(23):735-7. PubMed ID: 11191745
[TBL] [Abstract][Full Text] [Related]
25. [Clinical importance of organ-specific antibodies in ulcerative colitis and Crohn disease].
Goischke EM; Zilly W
Z Gastroenterol; 1992 May; 30(5):319-24. PubMed ID: 1378673
[TBL] [Abstract][Full Text] [Related]
26. Systematic review: new serological markers (anti-glycan, anti-GP2, anti-GM-CSF Ab) in the prediction of IBD patient outcomes.
Bonneau J; Dumestre-Perard C; Rinaudo-Gaujous M; Genin C; Sparrow M; Roblin X; Paul S
Autoimmun Rev; 2015 Mar; 14(3):231-45. PubMed ID: 25462578
[TBL] [Abstract][Full Text] [Related]
27. The search for the Holy Grail: autoantigenic targets in primary sclerosing cholangitis associated with disease phenotype and neoplasia.
Lopens S; Krawczyk M; Papp M; Milkiewicz P; Schierack P; Liu Y; Wunsch E; Conrad K; Roggenbuck D
Auto Immun Highlights; 2020 Mar; 11(1):6. PubMed ID: 32178720
[TBL] [Abstract][Full Text] [Related]
28. Elevated serum anti-carbonic anhydrase II antibodies in patients with ulcerative colitis.
Andoh A; Fujiyama Y; Yoshioka U; Sasaki M; Araki Y; Tsujikawa T; Bamba T
Int J Mol Med; 2002 May; 9(5):499-502. PubMed ID: 11956656
[TBL] [Abstract][Full Text] [Related]
29. Diagnosis and classification of Crohn's disease.
Laass MW; Roggenbuck D; Conrad K
Autoimmun Rev; 2014; 13(4-5):467-71. PubMed ID: 24424189
[TBL] [Abstract][Full Text] [Related]
30. Pancreatic autoantibodies and autoantibodies against goblet cells in pediatric patients with inflammatory bowel disease.
Kovacs M; Lakatos PL; Papp M; Jacobsen S; Nemes E; Polgar M; Solyom E; Bodi P; Horvath A; Muller KE; Molnar K; Szabo D; Cseh A; Dezsofi A; Arato A; Veres G
J Pediatr Gastroenterol Nutr; 2012 Oct; 55(4):429-35. PubMed ID: 22465933
[TBL] [Abstract][Full Text] [Related]
31. [Autoantibodies against the exocrine pancreas and against intestinal goblet cells in the diagnosis of Crohn's disease and ulcerative colitis].
Stöcker W; Otte M; Ulrich S; Normann D; Stöcker K; Jantschek G
Dtsch Med Wochenschr; 1984 Dec; 109(51-52):1963-9. PubMed ID: 6150841
[TBL] [Abstract][Full Text] [Related]
32. Loss of tolerance to gut immunity protein, glycoprotein 2 (GP2) is associated with progressive disease course in primary sclerosing cholangitis.
Tornai T; Tornai D; Sipeki N; Tornai I; Alsulaimani R; Fechner K; Roggenbuck D; Norman GL; Veres G; Par G; Par A; Szalay F; Lakatos PL; Antal-Szalmas P; Papp M
Sci Rep; 2018 Jan; 8(1):399. PubMed ID: 29321484
[TBL] [Abstract][Full Text] [Related]
33. Mucosal barrier, bacteria and inflammatory bowel disease: possibilities for therapy.
Merga Y; Campbell BJ; Rhodes JM
Dig Dis; 2014; 32(4):475-83. PubMed ID: 24969297
[TBL] [Abstract][Full Text] [Related]
34. Dietary antigens in Crohn's disease: antibodies to porcine pancreatic amylase.
Suzuki H; Fukuda Y; Koizuka H; Tomita T; Hori K; Suzuki M; O'Morain C
Am J Gastroenterol; 2008 Mar; 103(3):656-64. PubMed ID: 18028509
[TBL] [Abstract][Full Text] [Related]
35. Human glycoprotein-2 expressed in Brunner glands - A putative autoimmune target and link between Crohn's and coeliac disease.
Roggenbuck D; Goihl A; Sowa M; Lopens S; Rödiger S; Schierack P; Conrad K; Sommer U; Jöhrens K; Grützmann R; Reinhold D; Laass MW
Clin Immunol; 2023 Feb; 247():109214. PubMed ID: 36608744
[TBL] [Abstract][Full Text] [Related]
36. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease.
Dotan I; Fishman S; Dgani Y; Schwartz M; Karban A; Lerner A; Weishauss O; Spector L; Shtevi A; Altstock RT; Dotan N; Halpern Z
Gastroenterology; 2006 Aug; 131(2):366-78. PubMed ID: 16890590
[TBL] [Abstract][Full Text] [Related]
37. Glycoprotein 2 as a gut gate keeper for mucosal equilibrium between inflammation and immunity.
Zhang Z; Tanaka I; Nakahashi-Ouchida R; Ernst PB; Kiyono H; Kurashima Y
Semin Immunopathol; 2024 Jan; 45(4-6):493-507. PubMed ID: 38170255
[TBL] [Abstract][Full Text] [Related]
38. CD40 and CD86 upregulation with divergent CMRF44 expression on blood dendritic cells in inflammatory bowel diseases.
Vuckovic S; Florin TH; Khalil D; Zhang MF; Patel K; Hamilton I; Hart DN
Am J Gastroenterol; 2001 Oct; 96(10):2946-56. PubMed ID: 11693331
[TBL] [Abstract][Full Text] [Related]
39. CD4+ immune response as a potential biomarker of patient reported inflammatory bowel disease (IBD) activity.
Brandhorst G; Weigand S; Eberle C; Raddatz D; Karaus M; Oellerich M; Walson PD
Clin Chim Acta; 2013 Jun; 421():31-3. PubMed ID: 23485644
[TBL] [Abstract][Full Text] [Related]
40. A novel mucosal vaccine targeting Peyer's patch M cells induces protective antigen-specific IgA responses.
Shima H; Watanabe T; Fukuda S; Fukuoka S; Ohara O; Ohno H
Int Immunol; 2014 Nov; 26(11):619-25. PubMed ID: 24908678
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
